AngioDynamics, Inc. (NASDAQ:ANGO) Short Interest Update

AngioDynamics, Inc. (NASDAQ:ANGO) was the recipient of a large increase in short interest during the month of February. As of February 27th, there was short interest totaling 2,176,310 shares, an increase of 28.1% from the February 12th total of 1,699,336 shares. Based on an average daily volume of 276,482 shares, the days-to-cover ratio is presently 7.9 days. Approximately 5.6% of the company’s shares are sold short. Approximately 5.6% of the company’s shares are sold short. Based on an average daily volume of 276,482 shares, the days-to-cover ratio is presently 7.9 days.

Institutional Trading of AngioDynamics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Essex Investment Management Co. LLC raised its stake in shares of AngioDynamics by 41.9% in the third quarter. Essex Investment Management Co. LLC now owns 327,396 shares of the medical instruments supplier’s stock worth $3,657,000 after purchasing an additional 96,639 shares during the last quarter. Bastion Asset Management Inc. boosted its position in shares of AngioDynamics by 31.8% during the third quarter. Bastion Asset Management Inc. now owns 1,264,003 shares of the medical instruments supplier’s stock valued at $13,442,000 after buying an additional 304,960 shares during the last quarter. Stonepine Capital Management LLC purchased a new position in shares of AngioDynamics during the second quarter valued at approximately $765,000. Divisadero Street Capital Management LP grew its holdings in AngioDynamics by 253.7% during the second quarter. Divisadero Street Capital Management LP now owns 3,395,430 shares of the medical instruments supplier’s stock worth $33,683,000 after buying an additional 2,435,365 shares in the last quarter. Finally, AXQ Capital LP grew its holdings in AngioDynamics by 34.7% during the second quarter. AXQ Capital LP now owns 27,231 shares of the medical instruments supplier’s stock worth $270,000 after buying an additional 7,011 shares in the last quarter. 89.43% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on ANGO shares. Wall Street Zen lowered shares of AngioDynamics from a “buy” rating to a “hold” rating in a research note on Sunday, December 21st. Zacks Research raised shares of AngioDynamics from a “hold” rating to a “strong-buy” rating in a research note on Friday, January 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, AngioDynamics currently has an average rating of “Moderate Buy” and a consensus price target of $19.33.

AngioDynamics Stock Performance

Shares of ANGO stock opened at $10.60 on Friday. AngioDynamics has a fifty-two week low of $8.36 and a fifty-two week high of $13.99. The stock has a 50 day simple moving average of $10.80 and a two-hundred day simple moving average of $11.52. The company has a market cap of $436.93 million, a P/E ratio of -15.82 and a beta of 0.48.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.